The Story so Far - Our 5 year impact Report (2024) 28 Jan 2025 Our impact report showcases all the progress that's been made in just five years (2019-2024)
SGC Travel Grants Apply for funding to travel to a conference or workshop. We welcome all applications that are aligned with our strategy.
New study using real-world UK data supports the use of HER2-directed therapies for HER2-positive salivary gland cancers 03 Jan 2025 , by Katherine O'Connor Improving treatment options for patients with adenocarcinomas, not otherwise specified (NOS), and salivary duct carcinomas
Mucoepidermoid Carcinoma (MEC) & Warthin-like MEC Mucoepidermoid Carcinoma (MEC) including Warthin-like MEC
Our Mission Shane Draper, Salivary Gland Cancer UK Trustee, talks about how SGC UK is growing, our 8 aims and our work for patients
Our 8 Aims Through patient-clinician collaboration, we have formulated our 8 core aims, which drive our work
SGC Research Grants Apply for research funding. We welcome all applications that are aligned with our strategy.
